Combined therapy regimen shows promising results for treating metastatic prostate cancer

April 14, 2023 | Histopathology

Odoo text and image block

Prostate cancer is the most common cancer and he second leading cause of death among men in the United States according to the National Cancer Institute. Castration-resistant prostate cancer (CRPC), a late stage of prostate cancer, continues to have increasing incidence despite androgen blockade.

TALAPRO-2, a study led by Neeraj Agarwal M.D, Huntsman Cancer Institute’s Presidential Endowed Chair of Cancer Research, demonstrated that the combination of two oral medications showed positive results in individuals with prostate cancer and whose disease had already metastasized to other parts of the body.

Agarwal presented the results of one of his many Phase III trials at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The trial looked at the effectiveness of adding TALZENNA to XTANDI, the standard treatment where an androgen receptor blocker stops the male hormones from feeding the cancer. On the other hand, TALZENNA is a PARP inhibitor commonly used in treating breast cancer.

In the study, treatment plan for each patient was randomly selected and the clinical trials team monitored and made comparisons of side effects and results between two groups - those who received the two drugs, and those who received XTANDI plus placebo pill.Results showed that the combined therapy regimen exhibited significant development in radiographic progression-free survival. TALZENNA, combined with XTANDI, reduces the risk of disease progression or death by 37%.

Odoo text and image block

Phase III trials is the last phase before the FDA gets to approve the investigatory drug combination as a new treatment. The FDA decision is expected this year.  

Back To Top
We are fully compliant with the GDPR laws. We promise to safeguard your data and protect your privacy rights.